NEWS - Dec 20, 2019 Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool Read more
NEWS - Dec 9, 2019 Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares Read more
NEWS - Dec 3, 2019 Relmada Therapeutics Announces Pricing of Public Offering of Common Stock Read more
NEWS - Oct 15, 2019 Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression Read more
NEWS - Oct 14, 2019 Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15 Read more
NEWS - Oct 10, 2019 Relmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital Market Read more
NEWS - Sep 27, 2019 Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market Read more
